{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T03:29:19Z","timestamp":1767410959602,"version":"3.48.0"},"reference-count":15,"publisher":"Japanese Society of Internal Medicine","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2026,1,1]]},"DOI":"10.2169\/internalmedicine.5496-25","type":"journal-article","created":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T18:07:34Z","timestamp":1749665254000},"page":"111-117","source":"Crossref","is-referenced-by-count":0,"title":["Development of Severity Classification Criteria for Acute Neuro-Beh\u00e7et's Disease"],"prefix":"10.2169","volume":"65","author":[{"given":"Shunsei","family":"Hirohata","sequence":"first","affiliation":[{"name":"Department of Rheumatology, Nobuhara Clinic, Japan"},{"name":"Department of Rheumatology and Infectious Diseases, Kitasato University School of Medicine, Japan"},{"name":"Department of Internal Medicine, Teikyo University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirotoshi","family":"Kikuchi","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Teikyo University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuji","family":"Sawada","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Tokyo Medical University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshihiro","family":"Tono","sequence":"additional","affiliation":[{"name":"Department of General Medicine, Kitasato University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Izumi","family":"Kawachi","sequence":"additional","affiliation":[{"name":"Medical Education Center, Niigata University Graduate School of Medical and Dental Sciences, Japan"},{"name":"Department of Neurology, Brain Research Iinstitute, Niigata University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitsuhiro","family":"Takeno","sequence":"additional","affiliation":[{"name":"Department of Allergy and Rheumatology, Nippon Medical School Musashi Kosugi Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Akman-Demir G, Serdaroglu P, Tas\u00e7i B. Clinical patterns of neurological involvement in Beh\u00e7et's disease: evaluation of 200 patients. Brain 122: 2171-2182, 1999.","DOI":"10.1093\/brain\/122.11.2171"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Hisanaga K. Neuro-Beh\u00e7et disease, neuro-Sweet disease, and spectrum disorders. Intern Med 61: 447-450, 2022.","DOI":"10.2169\/internalmedicine.8227-21"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Hirohata S, Kikuchi H, Sawada T, et al. Clinical characteristics of neuro-Behcet's disease in Japan: a multicenter retrospective analysis. Mod Rheumatol 22: 405-413, 2012.","DOI":"10.3109\/s10165-011-0533-5"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Ishido M, Horita N, Takeuchi M, et al. Distinct clinical features between acute and chronic progressive parenchymal neuro-Beh\u00e7et disease: meta-analysis. Sci Rep 7: 10196, 2017.","DOI":"10.1038\/s41598-017-09938-z"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Hirohata S, Isshi K, Oguchi H, et al. Cerebrospinal fluid interleukin-6 in progressive Neuro-Behcet's syndrome. Clin Immunol Immunopathol 82: 12-17, 1997.","DOI":"10.1006\/clin.1996.4268"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Hirohata S. Potential new therapeutic options for involvement of central nervous system in Behcet's disease (Neuro-Behcet's syndrome). Curr Rheumatol Rev 3: 297-303, 2007.","DOI":"10.2174\/157339707782408973"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Hirohata S, Kikuchi H, Sawada T, et al. Recommendations for the management of Neuro-Beh\u00e7et's disease by the Japanese National Research Committee for Beh\u00e7et's Disease. Intern Med 59: 2359-2367, 2020.","DOI":"10.2169\/internalmedicine.4705-20"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Hirohata S, Kikuchi H, Sawada T, et al. Analysis of various factors on the relapse of acute neurological attacks in Beh\u00e7et's disease. Mod Rheumatol 24: 961-965, 2014.","DOI":"10.3109\/14397595.2014.891496"},{"key":"9","first-page":"1078","volume":"335","author":"International Study Group for Beh\u00e7et's disease null","year":"1990","unstructured":"9. International Study Group for Beh\u00e7et's disease. Criteria for diagnosis of Beh\u00e7et's disease. Lancet 335: 1078-1080, 1990.","journal-title":"The Lancet","ISSN":"https:\/\/id.crossref.org\/issn\/0140-6736","issn-type":"print"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Hatemi G, Christensen R, Bang D, et al. 2018 update of the EULAR recommendations for the management of Beh\u00e7et's syndrome. Ann Rheum Dis 77: 808-818, 2018.","DOI":"10.1136\/annrheumdis-2018-213225"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Saadoun D, Maalouf G, Vieira M, et al. Infliximab versus cyclophosphamide for severe Beh\u00e7et's syndrome. NEJM Evid 3: EVIDoa2300354, 2024.","DOI":"10.1056\/EVIDoa2300354"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Hibi T, Hirohata S, Kikuchi H, et al. Infliximab therapy for intestinal, neurological, and vascular involvement in Behcet disease: efficacy, safety, and pharmacokinetics in a multicenter, prospective, open-label, single-arm phase 3 study. Medicine (Baltimore) 95: e3863, 2016.","DOI":"10.1097\/MD.0000000000003863"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Yalcin Kehribar D, Gunaydin S, Ozgen M. Infliximab therapy in parenchymal neuro-Beh\u00e7et's disease: a single-center experience. Int J Rheum Dis 24: 1302-1307, 2021.","DOI":"10.1111\/1756-185X.14209"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Hibi T, Hirohata S, Hisamatsu T, et al. Real-world safety and effectiveness of infliximab in 255 patients with intestinal, neurological, and vascular Beh\u00e7et's disease: a post-marketing surveillance. Adv Ther 41: 4476-4497, 2024.","DOI":"10.1007\/s12325-024-02993-9"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Hirahara L, Kirino Y, Soejima Y, et al. Association of high disease activity and serum IL-6 levels with the incidence of inflammatory major organ events in Beh\u00e7et disease: a prospective registry study. Front Immunol 15: 1354969, 2024.","DOI":"10.3389\/fimmu.2024.1354969"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/65\/1\/65_5496-25\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T03:26:33Z","timestamp":1767410793000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/65\/1\/65_5496-25\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,1]]},"references-count":15,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.5496-25","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"type":"print","value":"0918-2918"},{"type":"electronic","value":"1349-7235"}],"subject":[],"published":{"date-parts":[[2026,1,1]]},"article-number":"5496-25"}}